Abstract library

38 results for "David".
#1158 A Phase II Study of Everolimus in Patients with FDG-PET Positive Intermediate Grade (Ki67 3-20%) Pancreatic Neuroendocrine Tumor
Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: ASSOC PROF Michael Michael
Authors:
Keywords: everolimus, FDG-PET
#880 Novel Succinate Dehydrogenase Subunit B Intronic Mutation in an Australian Kindred with Variable Clinical and Imaging Phenotype Necessitating Different Treatment Modalities Including 131-I MIBG and 177-Lutetium DOTATATE
Introduction: SDH B mutation has variable functional imaging phenotype challenging in terms of diagnosis, treatment modalities and follow-up.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Kevin Lee
Authors:
Keywords: SDHB, Paraganglioma
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors:
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Authors:
#205 Integrated Genome-Wide DNA Methylation and mRNA Expression Analysis of Pancreatic NETs Identifies Differential Activation of the Hypoxia Inducible Factor (HIF) Pathway Between Low and Intermediate Grade Tumors
Introduction: This is the first study to integrate DNA methylation and mRNA expression analysis in NETs. It is a powerful approach with which to identify disrupted biological pathways in NET pathogenesis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Authors:
#222 Results of Resection and Predictors of Outcome of Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) are uncommon with the incidence increasing significantly over the last decade. Surgical resection remains the only therapeutic option.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Mr Ravi Marudanayagam
Authors:
#399 Malignant Carotid Body Tumors (CBTs), Clinical Presentation, Investigations and Their Management
Introduction: Malignant CBTs are rare (incidence 0.012%) and their management is not well settled. We present 2 pts. with malignant CBTs to define their presentation, investigations done and treatment undertaken w/ FU.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors:
#440 The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing – MeDIP-seq
Introduction: Recently, the first cancer methylomes have been created which identified differential methylation at CpG island-shores (2kb upstream of CpG islands) to be of particular importance in the tumourigenic process.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Authors:
#527 Pheochromocytoma Molecular Analysis After Maternal Transmission of SDHD Mutation Elucidates Mechanism of Parent-of-Origin Effect
Introduction: In SDHD mutation families, paragangliomas and pheochromocytomas usually occur only after paternal transmission of the mutation. This important but unexplained parent-of-origin effect is not due to imprinting of the SDHD gene itself (as was initially suspected) since SDHD is biallelically expressed.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Edward Tobias
Authors:
#707 Neuroendocrine Carcinoma: Surgery of Peritoneal Metastasis
Introduction: Neuroendocrine tumor (NET)-derived peritoneal metastases (PM) are not really described nor taken into account in the literature, yet they exert an impact on overall survival (OS)
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Frédéric Dumont
Authors: